Last Price$19.45NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$17.51 (2)
Ask (Size)$21.89 (2)
Day Low / HighN/A - N/A
Volume3.9 M

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Alector Inc ( NASDAQ )

Price: $19.45
Change: -1.20 (5.81%)
Volume: 3.9 M
4:00PM ET 12/03/2021

Dynavax Technologies Corp ( NASDAQ )

Price: $13.17
Change: -1.53 (10.41%)
Volume: 4.4 M
4:00PM ET 12/03/2021

Iveric Bio Inc ( NASDAQ )

Price: $14.10
Change: -0.76 (5.11%)
Volume: 3.0 M
4:00PM ET 12/03/2021

Protagonist Therapeutics Inc ( NASDAQ )

Price: $32.27
Change: -0.42 (1.28%)
Volume: 476.8 K
4:00PM ET 12/03/2021

Morphic Holding Inc ( NASDAQ )

Price: $44.21
Change: -2.81 (5.98%)
Volume: 272.0 K
4:00PM ET 12/03/2021

Read more news Recent News

Insider Sell: Alector
6:31AM ET 11/15/2021 MT Newswires

Arnon Rosenthal, Director, Chief Executive Officer, on November 10, 2021, sold 110,000 shares in Alector (ALEC) for $2,750,000. Following the Form 4 filing...

Alector Shares AL001 Phase 2 Trial Results
3:03PM ET 11/12/2021 MT Newswires

Alector (ALEC) said Friday that its phase 2 clinical trial of AL001 showed that progranulin, a key regulator of immune activity in the brain, was restored...

Insider Sell: Alector
6:47AM ET 11/11/2021 MT Newswires

Arnon Rosenthal, Director, Chief Executive Officer, on November 08, 2021, sold 200,000 shares in Alector (ALEC) for $5,000,000. Following the Form 4 filing...

William Blair Starts Alector at Outperform
10:36AM ET 9/27/2021 MT Newswires

Alector (ALEC) has an average rating of buy and price targets ranging from $32 to $57, according to analysts polled by Capital IQ. (MT Newswires covers...

Company Profile

Business DescriptionAlector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. View company web site for more details
Address131 Oyster Point Boulevard
South San Francisco, California 94080
Number of EmployeesN/A
Recent SEC Filing12/03/20214
Chief Executive Officer & DirectorArnon Rosenthal
President, Chief Operating & Business OfficerShehnaaz Suliman
Chief Financial & Accounting OfficerLinda M. Rubinstein
VP-Technology & Digital HealthCharles Wolfus

Company Highlights

Price Open$20.82
Previous Close$20.65
52 Week Range$13.54 - 43.32
Market Capitalization$1.6 B
Shares Outstanding81.3 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.52
Beta vs. S&P 500N/A
Revenue$27.7 M
Net Profit Margin-16.62%
Return on Equity-12.96%

Analyst Ratings as of 11/24/2021

Consensus RecommendationConsensus Icon
Powered by Factset